Ruxolitinib in Treating Patients With Hypereosinophilic Syndrome or Primary Eosinophilic Disorders

Conditions:   BCR-JAK2 Fusion Protein Expression;   Blasts 20 Percent or Less of Peripheral Blood White Cells;   Blasts More Than 5 Percent of Bone Marrow Nucleated Cells;   Blasts More Than 5 Percent of Peripheral Blood White Cells;   Blasts Under 20 Percent of Bone Marrow Nucleated Cells;   Chronic Eosinophilic Leukemia, Not Otherwise Specified;   Eosinophilia;   Hepatomegaly;   Hypereosinophilic Syndrome;   JAK2 Gene Mutation;   Splenomegaly;   TEL-JAK2 Fusion Protein Expression Intervention:   Drug: Ruxolitinib Sponsors:   Stanford University;   Incyte Corporation Not yet recruiting
Source: ClinicalTrials.gov - Category: Research Source Type: clinical trials